ultifocal intraocular lenses (IOLs) enable spectacle independence 1 by providing several points of focus. A new generation of multifocal IOLs, known as trifocal IOLs (designed with three focal points) entered the European market in 2010, with the launch of the FineVision/MicroF IOL (PhysIOL, Liège, Belgium). Many studies describing optical bench testing and clinical outcomes for this IOL have been published since then.The presence of astigmatism in multifocal IOLs scatters each point of focus, resulting in multifocality failure. Therefore, astigmatism correction should also be a surgical goal. An accurate alignment of the toric IOL with the astigmatism axis is key for maximum vision correction. This can only be achieved if the IOL remains stable within the eye (ie, it must not rotate after implantation). The original FineVision/ MicroF IOL, a trifocal IOL model designed for microincision cataract surgery, was adapted with a new double C-loop haptic design that should guarantee the IOL's rotational stability. This new IOL model, which includes a toric component, was named POD FineVision.In this study, we assessed the effect on rotational and capsular centration stability of this new haptic design and whether or not this leads to an improved visual performance to validate the material and the design of the POD FineVision IOL for toric versions.
PATIENTS AND METHODS
Study deSignIn this randomized controlled trial, we compared the efficacy and rotational stability of two IOLs: a hydrophilic acryl-M ABSTRACT PURPOSE: To compare visual outcomes, rotational stability, and centration in a randomized controlled trial in patients undergoing cataract surgery who were bilaterally implanted with two different trifocal intraocular lenses (IOLs) with a similar optical zone but different haptic shape.
METHODS:Twenty-one patients (42 eyes) with cataract and less than 1.50 D of corneal astigmatism underwent implantation of one FineVision/MicoF IOL in one eye and one POD FineVision IOL in the contralateral eye (PhysIOL, Liège, Belgium) at IOA Madrid Innova Ocular, Madrid, Spain. IOL allocation was random. Outcome measures, all evaluated 3 months postoperatively, included monocular and binocular uncorrected distance (UDVA), corrected distance (CDVA), distance-corrected intermediate (DCIVA), and near (DCNVA) visual acuity (at 80, 40, and 25 cm) under photopic conditions, refraction, IOL centration, haptic rotation, dysphotopsia, objective quality of vision and aberration quantification, patient satisfaction, and spectacle independence.RESULTS: Three months postoperatively, mean monocular UDVA, CDVA, DCIVA, and DCNVA (40 cm) under photopic conditions were 0.04 ± 0.07, 0.01 ± 0.04, 0.15 ± 0.11, and 0.16 ± 0.08 logMAR for the eyes implanted with the POD FineVision IOL and 0.03 ± 0.05, 0.01 ± 0.02, 0.17 ± 0.12, and 0.14 ± 0.08 logMAR for those receiving the FineVision/MicroF IOL. Moreover, the POD FineVision IOL showed similar centration (P > .05) and better rotational stability (P < .05) than the FineVision/MicroF IOL. Regarding halos,...